Scholarlink

Objective <p>The aim of this study was to compare the Montreal Cognitive Assessment (MoCA) performances of people who report no, subclinical, and clinical symptoms of depression.</p> Methods <p>Data was collected for the randomized controlled trial BrainFit-Nutrition. A secondary data analysis of 1,111 participants (age ≥ 60 years; <i>M</i> = 68.4 years; 55.1% female) was performed. Depressive symptoms were assessed with the Patient Health Questionnaire-9 (PHQ-9), cognitive performance was assessed via the MoCA. Performance differences were tested with Kruskal-Wallis tests. Two sensitivity analyses were conducted, one with data from people with MCI and one with the original item structure of the MoCA.</p> Results <p>No differences were found in the MoCA total score or in visuospatial, executive functioning, attention, memory, or orientation subscores between individuals with no, subclinical, or clinical symptoms of depression. A sensitivity analysis also showed no differences.</p> Conclusion <p>Cognitive screening with the MoCA seems to be robust against depression and could therefore be used to screen for MCI regardless of depression level.</p> Trial registration <p>The study was prospectively registered at the International Standard Randomized Controlled Trial Number Registry on 23/11/2021 (ISRCTN 10560738).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

My patient might be depressed – can I still screen for MCI? Exploring cognitive performance on the MoCA in older people screened for depressive symptoms with the PHQ-9

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月24日

查看全文
  • Sophia Bösl,
  • Petra Scheerbaum,
  • Elmar Graessel,
  • Christian Kessler,
  • Julia-Sophia Scheuermann

摘要

Objective

The aim of this study was to compare the Montreal Cognitive Assessment (MoCA) performances of people who report no, subclinical, and clinical symptoms of depression.

Methods

Data was collected for the randomized controlled trial BrainFit-Nutrition. A secondary data analysis of 1,111 participants (age ≥ 60 years; M = 68.4 years; 55.1% female) was performed. Depressive symptoms were assessed with the Patient Health Questionnaire-9 (PHQ-9), cognitive performance was assessed via the MoCA. Performance differences were tested with Kruskal-Wallis tests. Two sensitivity analyses were conducted, one with data from people with MCI and one with the original item structure of the MoCA.

Results

No differences were found in the MoCA total score or in visuospatial, executive functioning, attention, memory, or orientation subscores between individuals with no, subclinical, or clinical symptoms of depression. A sensitivity analysis also showed no differences.

Conclusion

Cognitive screening with the MoCA seems to be robust against depression and could therefore be used to screen for MCI regardless of depression level.

Trial registration

The study was prospectively registered at the International Standard Randomized Controlled Trial Number Registry on 23/11/2021 (ISRCTN 10560738).